Clinical Trials Browser

Completed × Interventional × E-3810 × Clear all

NCT01283945 2024-07-25

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Solid Tumors

NCT02053636 2024-07-25

FINESSE

Phase 2 Completed

Breast Neoplasms

NCT03117101 2017-04-17

Study of the AL3810 in the Treatment of Advanced Solid Tumor

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors